An anonymous director reports

NYMOX UPDATE

Nymox Pharmaceutical Corp. has provided information to address requests it has received for further information concerning recent changes to the company's board of directors and the company's management.

Two former employees of the company proposed to the company a potential transaction. The company, its employees and the former employees are bound by an obligation not to disclose any details of the proposed transaction. The terms of the proposed transaction were thoroughly reviewed and it was determined that it was not in the best interests of the company or its shareholders to undertake the proposed transaction. The details of deliberations regarding the proposed transaction and the reasons for determining that the proposed transaction was not in the best interests of the company and its shareholders are confidential.

The company has been informed that one or more unauthorized letters sent by one or both of the former employees were disseminated to one or more shareholders and/or other third parties without the company's consent. The unauthorized letters may include confidential information, as well as other privileged information. As a result, the company requests that any shareholder or other third party who has received such unauthorized letters immediately destroy such letters, any electronic copies and any other records of such letters and abstain from any discussion or disclosure of the contents and information included in the unauthorized letters.

These two individuals were not involved with any important technical responsibilities of concern to shareholders and are being replaced (the company will make appropriate public disclosure when such roles have been filled).

The company has retained counsel.

Nymox is in the process of submitting applications for the approval to market the company's first-in-class drug, Nymozarfex, to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle-aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects, including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective, but it is not without risks and the discomforts of surgery, and BPH surgery has side effects such as permanent retrograde ejaculation for many patients.

About Nymozarfex (fexapotide)

Nymozarfex is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1,750 patients with over 1,600 injections administered, including over 1,200 fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.

We seek Safe Harbor.